Literature DB >> 7213522

The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

N H Holford, P E Coates, T W Guentert, S Riegelman, L B Sheiner.   

Abstract

1 A combined pharmacokinetic and pharmacodynamic model has been used to analyze the relationship between electrocardiographic (ECG) and systolic time intervals (STI) and changes in plasma concentration of quinidine after oral and i.v. doses in ten normal subjects. 2 The major effects of quinidine were on cardiac repolarization. Contrary to previous descriptions, we found no important change in the U wave, but the T wave was split into two peaks. The amplitude of these two peaks (T and T') was reduced, and the QT' peak and QT intervals were prolonged. The QT peak interval and systolic intervals did not change appreciably. There were small increases in the PQ and QRS intervals. 3 The effect of quinidine on the QT interval could be explained by a linear pharmacodynamic model. The equilibration between plasma and effect site had a half-time of 8 min. The slope of the pharmacodynamic model was 20.3 ms . mg 1(-1) after i.v. dosing and 33.5 ms . mg 1(-1) after oral dosing. 4 The difference in effect model slopes suggests pharmacologically active metabolites of quinidine are formed during absorption from the gut. 5 The total effect of a single oral dose of quinidine appears to be the same as the same dose given intravenously, even though only 70% of the oral dose reaches the systemic circulation as quinidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7213522      PMCID: PMC1401584          DOI: 10.1111/j.1365-2125.1981.tb01123.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Purkinje repolarization as a possible cause of the U wave in the electrocardiogram.

Authors:  Y Watanabe
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

2.  Effect of lidocaine and quinidine on steady-state characteristics and recovery kinetics of (dV/dt)max in guinea pig ventricular myocardium.

Authors:  C M Chen; L S Gettes; B G Katzung
Journal:  Circ Res       Date:  1975-07       Impact factor: 17.367

3.  Inhibition of adrenergic vasoconstriction by quinidine.

Authors:  P G Schmid; L D Nelson; A L Mark; D D Heistad; F M Abboud
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

4.  Quantitative correlation of plasma and myocardial quinidine concentrations with biochemical and electrocardiographic changes.

Authors:  Y W Cho
Journal:  Am Heart J       Date:  1973-05       Impact factor: 4.749

5.  Carbon-13 magnetic resonance study. Structure of the metabolites of orally administered quinidine in humans.

Authors:  F I Carroll; D Smith; M E Wall
Journal:  J Med Chem       Date:  1974-09       Impact factor: 7.446

6.  Effects of quinidine on venous responses to adrenergic and nonadrenergic constrictor stimuli: indirect evidence of two sites of action in vascular smooth muscle.

Authors:  L D Nelson; P G Schmid; D Holmsten; A L Mark; D D Heistad; F M Abboud
Journal:  Proc Soc Exp Biol Med       Date:  1974-06

7.  The electrophysiological effects of intramuscular guinidine on the atrioventricular conducting system in man.

Authors:  M E Josephson; S F Seides; W P Batsford; G M Weisfogel; M Akhtar; A R Caracta; S H Lau; A N Damato
Journal:  Am Heart J       Date:  1974-01       Impact factor: 4.749

8.  The effect of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration.

Authors:  R H Heissenbuttel; J T Bigger
Journal:  Am Heart J       Date:  1970-10       Impact factor: 4.749

9.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

10.  Normal myocardial contractile state in the presence of quinidine.

Authors:  W Markiewicz; R Winkle; G Binetti; R Kernoff; D C Harrison
Journal:  Circulation       Date:  1976-01       Impact factor: 29.690

View more
  38 in total

Review 1.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

2.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Pharmacodynamic measurements of methyl nicotinate percutaneous absorption.

Authors:  R H Guy; E Tur; B Bugatto; C Gaebel; L B Sheiner; H I Maibach
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

4.  Drug concentration, binding, and effect in vivo.

Authors:  N H Holford
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

Review 5.  Early QT assessment--how can our confidence in the data be improved?

Authors:  Borje Darpo; Christine Garnett
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 7.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

8.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors:  E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Kinetics of ajmaline disposition and pharmacologic response in beagle dogs.

Authors:  M Yasuhara; Y Hashimoto; K Okumura; R Hori; T Sakurai; C Kawai
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

10.  Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.

Authors:  A Rakhit; T W Guentert; N H Holford; J Verhoeven; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.